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1. ABSTRACT 
Increased production of inflammatory cytokines such as tumor necrosis factor-α (TNF-α) 
and reactive oxygen species by glia in the central nervous system (CNS) is a hallmark of 
a variety of inflammatory and degenerative brain diseases.  
Axonal transport of mitochondria or synaptic vesicle precursors via the kinesin motor 
protein is essential to keep the integrity of the axon and synapse. Disturbance of axonal 
transport and accumulation of axonally transported organelles is an early sign of 
neuroinflammatory diseases such as multiple sclerosis, brain injury and Alzheimer’s 
disease.  
We studied whether axonal transport is compromised by acute exposure to inflammatory 
mediators produced by activated glia. We dissected the transport of the synaptic vesicle 
precursor proteins synaptophysin and synaptotagmin tagged with green fluorescent 
protein (synaptophysin-EGFP and synaptotagmin-EGFP). We found that microglia pre-
stimulated by inflammatory cytokines to produce nitric oxide (NO) and tumor necrosis 
factor-α (TNF-α) focally suppressed the axonal motility of labeled vesicle precursors at 
the point of contact between activated glia and axons, as measured using confocal 
microscopy of fluorescence recovery after photobleaching (FRAP).  
We found that direct application of either TNF-α or a short-term NO donor to cultured 
hippocampal neurons inhibited axonal motility of both synaptophysin-EGFP and 
synaptotagmin-EGFP. Furthermore, TNF-α inhibited axonal transport of mitochondria in 
a similar manner. 
Consistently, TNF-α induced axonal transport impairment normalized again after 6-8 
hours of TNF-α application. 
Inhibition of axonal transport by NO or TNF-α was associated with a significantly 
increased fraction of immobile particles. Furthermore, inhibition of axonal transport was 
dependent on phosphorylation of c-jun NH2-terminal kinase (JNK).  
In particular, we show that both NO and TNF-α stimulated phosphorylation of JNK in 
axons. In experiments with both genetically labeled mitochondria and synaptic vesicle 
precursors, we observed that the velocity of the remaining mobile particles was largely 
unchanged. This suggested a model where TNF-α produced by activated glial cells in 
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inflammatory or degenerative brain diseases acts on axons by inhibition of cargo 
transport and dissociation kinesin motor protein from microtubules.  
Confocal microscopy and lifetime-based Förster resonance energy transfer (FRET) 
analysis were performed on primary cultured neurons to analyse the effect of TNF-α on 
the axonal mitochondrial transport system. TNF-α induced detachment of the heavy chain 
kinesin family-5B (KIF5B) protein from tubulin in axons, but not cell bodies as 
determined by lifetime based FRET analysis. Dissociation of KIF5B from tubulin after 
TNF-α treatment was also dependent on phosphorylation of JNK.  
Thus, overt production of inflammatory mediators by activated microglial cells blocks the 
motility of synaptic vesicle precursors and mitochondria via phosphorlyation of JNK and 
may cause axonal and synaptic dysfunction in inflammatory and degenerative brain 
diseases. 
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 2. INTRODUCTION 
2.1 Molecular mechanisms of brain injury 
The molecular mechanism of axonal injury in inflammatory brain diseases such as 
multiple sclerosis [1] and synapse loss in neurodegenerative diseases such as Alzheimer’s 
disease [2] is not known. Several studies observed a close association between the 
number of activated microglial cells and axonal injury in multiple sclerosis [3, 4], 
microbial infection [5] and brain injury [6, 7]. Furthermore, accumulation of β-amyloid 
precursor protein (APP), a sign of axonal transport disturbance, is observed in several 
inflammatory brain diseases including multiple sclerosis [8], microbial infections [5, 9], 
mechanical injury [10] and ischemia [11].  
Intact axonal transport via kinesin motor protein is fundamental for normal function of 
synaptic connections and targeted deletion of kinesin motor proteins results in axonal 
degeneration [12].  
Recently, it was suggested that axonal transport impairment is involved in early 
development of neurodegenerative diseases [13]. However, this question has not been 
addressed in detail. 
Whilst pathologies associated with the later stages of interaction between axons and 
activated microglia such as axonal trans-section, are well characterized [14], little is 
known about the initial response of healthy axons to activated microglia. Such 
information would be valuable for the development of novel therapeutical approaches, 
which could aim to limit the damage caused to healthy nervous tissue caused by activated 
microglia [15]. 
 
2.2 Microglial activation in the central nervous system   
The important role of microglia in various pathological conditions was first recognized 
by del Rio-Hortega, who first identified this class of cells [16]. Most of brain pathologies 
involve the microglia [17]. Microglial cells are the resident macrophages of the CNS, 
which form the brain’s first line of defense and are in control of the immune response in 
the brain. Microglia form an essential link between the CNS, isolated from the rest of the 
immune system by the blood-brain barrier, and the general immune system.  
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Their nature and identity have long been debated but it is now generally accepted that 
they are similar to cells of the mononuclear phagocyte lineage, and thus are unlike all 
other cell types in the CNS [18, 19]. However, some few laboratories suggest that, based 
on in vitro experiments, microglia may be true glia of neuroectodermal lineage [20]. 
Microglia are capable of responding to very subtle alterations in their microenvironment, 
such as imbalances in ion homeostasis, before any signs of disease can be histologically 
detected [21]. One characteristic feature of microglia is their activation in the CNS at a 
very early stage in response to injury [22-25]. Microglia are generally inactive, or resting, 
but as was observed over a century ago, they rapidy change their morphology upon 
activation [26]. Microglial activation takes place in a rather stereotypic pattern, 
irrespective of the cause of the lesion. Activation of microglia displays a repertoire in 
terms of proliferation, migration to the site of injury, characteristic morphological, 
immunophenotypical and functional changes. 
The development of resting microglia cells into full blown phagocytes occurs in response 
to cell death, and especially that of neuronal death. The shape of activated microglia can 
be highly variant, and depends on the particular pathology the microglia are responding 
to. The scavenger function of microglia becomes evident particularly under ischaemic or 
traumatic conditions [16, 26]. Resident microglia play a part in tissue repair after injury, 
an similar to that of resident macrophages in peripheral organs. Both microglia and 
astrocytes are needed for tissue reconstitution after lesions, involving control of the 
blood-brain barrier and of the invasion of haematogenous cells, removal of pro-
inflammatory cytokines and their downregulation by TGF-β1. 
In their role as phagocytes, they destroy invading micro-organisms, remove potentially 
deleterious debris, promote ensuing tissue repair by secreting wound-healing factors and 
thus facilitate the return to tissue homeostasis. Cytotoxic effects contribute to the function 
of microglia as tissue guardians in the brain [27]. 
Activated microglia are capable of releasing several potentially cytotoxic substances in 
vitro, such as free oxygen intermediates, NO, proteases, arachidonic-acid derivates, 
excitatory amino acids, quinolinic acid and cytokines [27-29].  
Microglial activation is controlled by a positive feedback mechanism- resting microglia 
can be activated by inflammatory cytokines, which are in turn produced by the microglia 
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themselves- leading to damage of healthy tissue surrounding the site of microglial 
activation. TNF-α produced by microglia can cause bystander damage during 
demyelination. Free oxygen radicals released by microglia have a neurotoxic effect in co-
cultures of neurons and microglia [30, 31] . 
 
2.3 Motor proteins and axonal transport 
Many studies have been performed to understand the nature and characteristics of 
organelle tansport, particularly in highly polarized cells such as neurons [32-34]. A better 
understanding of the molecular nature of transport complexes can give many insights to 
how a cell services and regulates its many biological requirements. 
A wide spectrum of motor proteins has been identified, which can be divided into two 
general classes: proteins responsible for anterograde transport (kinesins) and those 
utilized for retrograde transport (dyneins). These motors all share some common features, 
such as motor domains and a c-terminal which forms the interface between the motor 
protein and that motor protein’s specific cargo. 
It is widely supposed that different motor proteins, which all have different enzymatic 
characteristics (thus translating as different movement behaviour on the microtubule 
network) are responsible for different cargoes. Thus one can indirectly observe the 
behaviour of groups of motor proteins by monitoring the transport of their cargoes.  
 Synaptic vesicle precursors containing synaptophysin are largely synthesized and pre-
assembled in the cell body and then transported over long distances to the axonal 
terminals usually via the kinesin motor protein KIF1A [35]. 
Synaptophysins are N-glycosylated membrane proteins, reported to interact with 
synaptotagmin I on synaptic vesicle membranes [36]. Immunoprecipitations of synaptic 
vesicles from rat brain with antibodies to synaptophysin demonstrate that synaptoporin is 
colocalized with synaptophysin on the same vesicles, although they do not interact with 
each other [37]. The presence of these two highly related proteins on the same vesicle 
suggests that they have similar but nonidentical functions. A mouse knockout of 
synaptophysin alone produces no detectable phenotype (although a defect in synaptic 
transmission was observed in a synaptophysin/synaptogyrin double mutant, suggesting 
functional redundancy for these proteins) [38]. All these proteins can potentially be used 
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as marker of vesicle transport, and in the following study we chose to utilize both 
synaptophysin and synaptotagmin I. 
 
2.4 Mitochondria in the axon 
The mitochondrion derives its name from the Greek mitos (thread) + khondrion (granule), 
recognising their characteristic shapes. While generally very similar in diameter, 
mitochondria can have very different overall structures. In neurons, they range from 1 to 
20 µm in length [39]. Observations of fluorescently labelled mitochondria in living cells 
have shown them to be dynamic organelles capable of dramatic changes in shape. 
Mitochondria can fuse with one another, or split in two, a process which involves 
Dyamins [40]. Mitochondria have two functional membranes: the outer mitochondrial 
membrane completely encloses the organelle, serving as its outer boundary. The inner 
mitochondrial membrane is thrown into folds, or cristae, that project inward. The cristae 
surface houses the machinery needed for aerobic respiration and ATP formation, and 
their folded form increases that capacity by increasing the surface area of the inner 
mitochondrial membrane. Although the primary function of mitochondria is to convert 
organic materials into cellular energy in the form of ATP, mitochondria play an important 
role in most important metabolic processes [41-43]. They generate the ATP necessary to 
maintain transmembrane ionic gradients and are thought to play a role in the regulation of 
cytoplasmic calcium. Because diffusion of both ATP and calcium ions is limited in 
cytoplasm [44], the distribution of mitochondria is thought to tightly reflect the 
distribution of energy need and calcium flux. Thus, the movement and redistribution of 
mitochondria is vital for maintaining cellular homeostasis. 
Active transport in cells is largely driven by three classes of motors: kinesins, dyneins 
and myosins. All of them need ATP for complete their task. Thus, the positioning of 
ATP-producing mitochondria in the cell has the potential to strongly affect transport 
characteristics of that cell.  
Mitochondria themselves depend on motor proteins for their movement. So far, it is 
known that multiple anterograde moving motor proteins (Kif5B, Kif1B) are involved, 
and that retrograde transport of mitochondria is most likely mediated by dynein [45] but 
the regulation of this process is still not well studied. In particular, very little is known 
   
 11
about mechanisms which are involved in the very fast switching evidently required to 
change motion from anterograde to retrograde directions [45, 46]. Some studies propose 
´super complexes´ of multiple motor proteins with different movement characteristics 
[45]  which may explain rapid changes in direction.  
 
2.5 Adaptor proteins for kinesins 
Transport of synaptic vesicle precursor components is a highly regulated process. Several 
studies indicate that c-Jun N-terminal kinase (JNK) interacting proteins (JIP) serve as 
scaffolding proteins and associate with the kinesin motor protein family and cargo 
receptors. Particularly, data in C. elegans showed that unc-16, encoding a homolog of the 
mouse scaffolding protein JIP3, physically interacts with JNK and JNK kinases [47]. 
Pioneering work by the group of Goldstein in Drosophila melanogaster described that a 
homologue of the mammalian scaffolding protein JIP3 linked conventional kinesin-I to 
an unknown class of vesicles [48]. Data in C. elegans showed that unc-16, encoding a 
homologue of JIP3, physically interacts with JNK and JNK kinases [49]. Mutations of 
unc-16 or JNK resulted in mislocalization of synaptic vesicle markers such as 
synaptobrevin [47] and synaptotagmin I [49]. Also JIP1 and JIP2 have been identified to 
associate with and be cargoes of kinesin-I [50].  
Furthermore, the JNK signaling scaffold protein JIP-1b connects the motor protein 
kinesin light chain to the synaptic vesicle protein APP and enables protein 
phosphorylation by JNK [51]. APP is widely supposed to be a transmembrane cargo 
receptor of synaptic precursor vesicles [52]. 
The scaffolding JIPs are also involved in the organization and facilitation of JNK 
signaling implicated in multiple processes, allowing a cell to mount an appropriate 
response to extracellular stress [53]. The finding that multiple types of JNK scaffolding 
proteins interact with kinesin-I and that JNK scaffolding proteins are involved in JNK 
signaling raises the question whether JNK signaling regulates axonal transport.  
 
2.6 Technical approach to determine dynamics of axonal cargos 
A well-known imaging technique used to study the motility of fluorescence molecules in 
living sample is fluorescence recovery (or redistribution) after photobleaching (FRAP) 
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[54]. 
A high intensity light is used to irreversibly photo bleach a population of fluorophores  in 
a target region, recovery of that fluorophore in that region is indicative of the dynamics. 
Quantification of fluorescence intensity over time is used to determine which fractions of 
particles are stationary or mobile, and can be used to infer velocities of populations of 
particles [54, 55]. 
In this thesis, fluorescence recovery after photobleaching (FRAP) was applied to analyze 
the axonal motility of synaptophysin tagged with enhanced green fluorescence protein 
(synaptophysin-EGFP) in living cultured hippocampal neurons in response to 
inflammatory stimuli such as activated microglia and its inflammatory mediators nitric 
oxide (NO) and tumor necrosis factor-α (TNF-α). 
 
2.7   Technical approach to determine interaction between motors and tubulin track 
In this study, we used fluorescence resonance energy transfer (FRET) as a non-invasive 
imaging method to characterize the interaction of kinesin motor proteins with 
microtubules in primary neuronal cultures. FRET, also called Förster transfer, named for 
Theodor Förster who, in the 1940s, quantitatively described the phenomenon, originates 
from a nonradiative dipole–dipole interaction between a donor and an acceptor 
fluorophore. The strong dependence of the energy transfer rate kT and hence the energy 
transfer efficiency ET on the donor–acceptor distance R, is described by: 
 
 
When two fluorophores are extremely close, the distance between these sites can be 
measured using the above formalism [56]. In particular, tD, donor fluorescence lifetime in 
the absence of acceptor; R0, Förster distance at which ET is 50%; R0 is dependent on the 
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spectral overlap of the fluorophore pair used and typically has a value of 20–90 A°, 
enables the calculation of fluorophore distances in the range 10–100 A° from their energy 
transfer efficiency.  
The fluorescence lifetime is a direct indicator of this energy transfer rate from the excited 
molecules to the acceptor molecules [57]. Since the lifetime does not depend on the 
concentration of the fluorophore, FLIM is allows a more consistent measurement of 
energy transfer between fluorophores in samples with varying fluorescence intensity. 
With FLIM techniques, FRET results are obtained from a single lifetime image of the 
donor [58-60]. The fluorescence lifetimes of typical fluorophores used in cell imaging are 
typically of the order of a few ns.  
In this study, fluorescence lifetime imaging was achieved by time-domain techniques use 
pulsed excitation and record the fluorescence decay function directly, by time correlated 
photon counting [61].  
Time-correlated single photon counting (TCSPC) combines a near-ideal counting 
efficiency with extremely high time-resolution. For a full description of equipment and 
data analysis, see “Materials and Methods”. 
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3. MATERIAL AND METHODS 
3.1 Neuronal cultures and transfection with EGFP or synaptophysin-EGFP 
Neuronal cultures were prepared from hippocampi of C57BL/6 mice embryos (E17) as 
described previously [62]. Hippocampi were isolated, dispersed mechanically and seeded 
in biomembrane optical dishes (Helmut Saur, Germany) or 4-well chamber culture dishes 
(Nunc GmbH&Co. KG, Germany). The dishes were pretreated with poly-L-ornithin (0.01 
mg/ml, Sigma, Germany) and laminin (10 µg/ml, Sigma, Germany). The cells were 
cultured in neuronal culture medium (BME, GibcoBRL, Invitrogen GmbH, Germany) 
supplemented with 2% B-27 supplement, (GibcoBRL, Invitrogen GmbH, Germany), 1% 
glucose (45 % glucose, Sigma, Germany) and 1% fetal calf serum (FCS, PAN Biotech 
GmbH, Germany). Cells were cultured for 5-10 days to obtain morphologically mature 
neurons. 
Transfection of neurons was performed with a plasmid expressing EGFP (enhanced green 
fluorescent protein) alone or synaptophysin (rat  synaptophysin p38) tagged with EGFP at 
the c-terminus under control of the human synapsin I promoter as previously described 
[15]. The plasmid p(synapsin).EGFP was kindly provided by Dr. S. Kügler [63], Dept. of 
Neurology, University of Göttingen, and p(CMV).p38-EGFP was kindly provided by Dr. 
C. Kaether, EMBL, Heidelberg [64]. 
Both genes were subcloned to produce the p(synapsin).synaptophysin-EGFP plasmid. In 
detail, EGFP was removed from the p(synapsin).EGFP plasmid by NotI/NheI restriction 
digestion. Synaptophysin -EGFP was cut by NotI/NheI restriction digestion and 
subcloned in the p(synapsin)-vector backbone. The subcloning was verified by control 
restriction enzyme digestion. The plasmid was purified using the EndoFree Maxi Kit 
(Qiagen, Germany). Transfection was performed during seeding of the neuronal cells by 
the Effectene Transfection Kit (Qiagen, Germany). The cells were incubated for 30 
minutes with 0.5 µg plasmid DNA per 1x106 cells, 6 µl enhancer, 12 µl Effectene and 85 
µl buffer. After transfection, the cells were washed in phosphate buffered saline (PBS) 
and suspended in neuronal culture medium. The average transfection efficiency was 
approximately 0.5% and the majority of transfected neurons showed plasmid expression 
from day 3-5 until day 10-14. After transfection neurons were cultured for 5-10 days 
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before being used in the experiments. Neurons were treated with the short term NO donor 
(300 µM DEA/NONOate, Alexis Corp.), cGMP (0.2 mM 8-Bromo-cGMP, Sigma) or the 
NO synthase inhibitor aminoguanidine (2 mM, Sigma) as indicated in the text and 
figures. Neurons were pre-treated for 30-40 minutes with the JNK inhibitor (100 nM JNK 
Inhibitor II, Alexis Corp.) as indicated in the text and figures. 
 
3.2 Microglial cultures 
Microglial cells were prepared from the hippocampal region of postnatal day 5 (P5) 
C57BL/6 mice as previously described [65]. Briefly, meninges were removed 
mechanically and the cells were cultured in basal medium (BME, GibcoBRL, Invitrogen 
GmbH, Germany, 10% fetal calf serum (FCS, PAN Biotech GmbH, Germany), 1% 
glucose and 1% L-glutamine for 25-30 days to form a confluent cell monolayer. To 
collect microglial cells the cultures were shaken on a rotary shaker (220 rpm) for 2 hours. 
The detached microglial cells were cultured in normal culture dishes for 1 hour and non-
adherent cells were removed. Purity of the isolated microglia was confirmed by flow 
cytometry analysis. For this, cells were incubated for 1 hour on ice with anti-
CD11b/CD18 biotinylated antibody (1: 100, PharMingen, BD Biosciences, USA) or 
negative isotype control antibody (PharMingen) and thereafter with streptavidin-FITC 
(1:100, Dianova, Hamburg, Germany). Analysis was done with a FACScalibur flow 
cytometer (BD Biosciences, USA). Life gating was performed with propidium iodide 
(Sigma, Germany) and the percentage of CD11b/CD18 cells was determined according 
the isotype control (data not shown).  
Microglial cells were cytokine-stimulated by combined treatment with interferon-gamma 
(recombinant murine IFN-gamma, 100 U/ml, HyCult Biotechnology, The Netherlands) 
and interleukin-1β (murine IL-1β, 10 ng/ml, Roche Molecular Biochemicals) for 72 hours 
as indicated in the text. Microglial cells were pre-treated for 60 minutes with the NOS 
inhibitor aminoguanidine (2 mM; Sigma) as indicated in the text. Microglial cells were 
CellTracker-labeled according the manufacturers instructions (CellTracker orange 
CMTMR, Molecular Probes, Leiden, The Netherlands) and added in a fixed ratio of 1:2 
(microglia : neurons) to the neuronal cultures.  
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3.3 Transfection of neurons with pMH4.mito-YFP 
The pMH4-HSYN-Mito -EYFP vector is designed to be used for the fluorescent labeling 
of mitochondria. Fluorescence can be observed in living or fixed neurons by microscopy.  
The plasmid encodes a fusion of EYFP and the mitochondrial targeting sequence from 
subunit VIII of human cytochrome c oxidase, under the human synapsin promotor. The 
EYFP gene (enhanced yellow fluorescent protein with the emission of the chromophore 
to yellow-green from green. The fluorescence excitation maximum of EYFP is 513 nm, 
and the emission spectrum has a peak at 527 nm. In addition to the four chromophore 
mutations, the coding sequence of the EYFP gene contains more than 190 silent base 
changes corresponding to human codon-usage preferences, which increase the 
translational efficiency of the EYFP transcript. Mitochondrial targeting sequence from 
subunit VIII of human cytochrome c oxidase linked in frame with eYFP, and sequenced. 
The plasmid was purified using EndoFree Maxi Kit (Qiagen, Germany). Transfection 
was performed during seeding of the cells by the Effectene Transfection Kit (Qiagen, 
Germany) with 0.5-1 µg DNA per 1x106 cells, 4-8 µl enhancer, 12 µl Effectene and 85 
µl buffer for a period of 30 min. After transfection, the cells were washed in PBS and 
suspended in BME-basal neuronal medium. The cells were seeded in 4-well chambers 
(Nunc GmbH&Co. KG, Germany) or in membrane-bottom optic dishes (Helmut Saur, 
Germany) with a density of 150 000 cells/ml.  
 
3.4 In vivo imaging and FRAP analysis 
FRAP was performed using Leica TCS laser scanning confocal microscopy with 40x  
objective as described with some modifications [66]. The medium of the neuronal 
cultures was removed and substituted with image buffer containing 142 mM NaCl, 5.4 
mM KCl, 1.8 mM CaCl2, 1 mM NaH2PO4, 25 mM HEPES, 5 mM glucose, 0.8 mM 
MgCl2 MgSO4 in ddH2O, pH=7.4. The cell culture dishes were placed on the heated 
stage in a heated chamber of a Leica LSC confocal microscope (Leica, Germany) and 
kept during the analysis at 35-37 °C. Bleaching was performed with 100% laser power 
and zoom area 32x within 20 scanning frames of an 20 µm x 20 µm area along a 
synaptopyhsin-EGFP or EGFP transduced axon. In all experiments bleaching was more 
than 80 % assuming a Gaussian distribution of remaining GFP-labeled molecules. For 
   
 17
postbleaching in vivo imaging, the laser power was turned to minimum and further 
reduced to 10-20% according the software control panel to avoid photobleaching and 
phototoxicity. Photobleaching with this reduced laser power was less than 1 %. Samples 
were imaged each 10 - 60 seconds over 15 minutes after photobleaching. Collected data 
were fitted to the following equation:  
 
F(t) = span (1-e-kt) + bottom 
 
The bottom was defined as the intensity of the first image after photobleaching, plots 
were generated from background subtracted images using Matlab scripts, following 
analysis [55]. Briefly the signal F(t) was measured, as mentioned, in an area of interest 
and analyzed, normalized and plotted. Each normalization was made to obtain a range of 
F(t) between [0-1] arbitrary units, where 1 is the initial fluorescence intensity, and 0 the 
intensity immediately after photobleaching.      
The half-time value t½ was calculated accordingly. The final fluorescence intensity F(∞) 
was less then the pre-bleaching fluorescence intensity since a proportion of the 
fluorescence molecules were not mobile. The mobile fraction (i.e. those particles moving) 
was defined as the span of the fluorescence recovery after photobleaching.  
Immunohistochemestry for neurofilaments and tau after FRAP was performed to show 
that there is not phototoxicity or cytoskeleton damage after bleaching, Fig. 15.   
 
3.5 In vivo imaging by tracking mitochondria 
The neuronal cells were cultured in LabTek chambered coverglass slides. The original 
medium of the neuronal cultures was removed and substituted with image buffer 
containing 142 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM NaH2PO4, 25 mM 
HEPES, 5 mM glucose, 0.8 mM MgCl2 in ddH2O, pH=7.4. The cell culture dishes were 
placed on the heated stage of the confocal microscope Leica LSC (Leica, Germany) and 
kept during the analysis at 35-37 oC.  
Mitochondria were tracked through a series of picture (each frame every 20 sec) taken by 
confocal microscopy.  
We used View5d (image plugin made by Dr. Rainer Heintzmann, 
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www.gwdg.de/~rheintz/View5D/ ) combined with Matlab. The analysis was performed by 
manual tracking and by kymograph, a graphical representation of spatial position over 
time in which one spatial axis represents time. After analysis, we could define velocity, 
direction, mobile fraction of mitochondria and immobile fraction of mitochondria to 
compare in different situations. 
 
3.6 Detection of iNOS gene transcripts, TNF-α and NO release by microglia 
RNA was isolated from microglia either untreated or treated for 72 hours with IFN-
gamma (100 U/ml) and IL-1β (100 U/ml) by the RNEasy Kit (Qiagen). Reverse 
transcription of RNA was performed with Moloney murine leukemia virus transcriptase 
(Invitrogen) and hexamer random primers (Roche Molecular Biochemicals). Forward and 
reverse primers for iNOS, TNF α and GAPDH were chosen from two different exons and 
were, respectively, iNOS (5'-AAGCTGCATGTGACATCGAC-3' ; 5'-
TGCTGAAACATTTCCTGTGC-3') , TNF ( 5-GGGGTGATCGGTCCCCAAAGG-3 ; 
5-CGGGGCAGCCTTGTCCCTTG-3 ) ; and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (5'-TCCGCCCCTTCTGCCGATG-3'; 5'-CACGGAAGGCCATGCCAGTGA-
3’). The PCR reaction was performed with the transcribed cDNA probes by 30 cycles 
with deoxyribonucleotide triphosphates (Amersham Bioscience),  denaturated primers 
(MWG, Germany), Ampli Taq polymerase (Perkin-Elmer, Roche Molecular Systems) on 
a programmed thermocycler (MultiCycler, MJ Research Inc.). PCR amplification with 
primers for GAPDH served as control for the quality and quantity of the transcribed 
cDNA. PCR reactions were analyzed on an agarose gel containing ethidium bromide, 
Fig. 1b. 
To measure the release of NO from microglial cells, the Griess Reagent System 
(Promega) was used according the manufacturers guidelines. The amount of nitrite (NO2) 
was measured as a stable and nonvolatible breakdown product of NO. The system was 
calibrated with a standard curve. The detection limit was 2.5 µM nitrite. Microglial cells 
were treated for 72 hours with IFN-gamma (100 U/ml) and IL-1β (100 U/ml), Fig 1a.  
 
3.7 Immunohistochemistry  
Hippocampal neurons transfected with synaptophysin-EGFP or synaptotagmin-EGFP 
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were cultured for 1 week, fixed with 4% paraformaldehyde, permeabilized with 0.1% 
Triton X-100, and incubated with a mouse monoclonal antibody specific for tau 
microtubule-associated protein (tau-1, 1:200, clone PC1C6; Chemicon), followed by 
secondary fluorochrome Cy3-conjugated goat antibody directed against mouse IgG 
(1:200; Dianova). Alternatively, fixed neurons were labeled with mouse monoclonal 
antibody specific for synaptobrevin/VAMP2 directly conjugated with Oyster 556 (1:200, 
IgG1; Synaptic Systems)..A mouse monoclonal antibody specific for phosphorylated 
JNK (1:200,  Santa Cruz Biotechnology, Santa Cruz, CA), followed by secondary 
fluorochrome Cy3-conjugated goat antibody directed against mouse IgG 
(1:400,Dianova). Subsequently, after washing, cells were incubated with an axon-specific 
mouse monoclonal antibody directed against tau (tau-1, 1:200, PC1C6; Chemicon) and 
secondary FITC goat antibody directed against mouse IgG(1:400; Dianova).  
Rat monoclonal antibodies directed against TNFRI (2 µg/ml1:50; HM-104; Biermann, 
Bad Nauheim, Germany) and TNFRII (1:502 µg/ml; HM-102; Biermann) followed by 
secondary fluorochrome Cy3FITC-conjugated goat antibody directed against rat IgG (10 
µg/ml1:200; Dianova).  
A neuron-specific mouse monoclonal antibody specific for β-tubulin IIIMAP2 (1 µg /ml 
1:400; Sigma) and secondary FITC Cy3 goat antibody directed against mouse IgG (10 
µg/ml 1:200; Dianova). Baseline labeling was determined with rat control antibodies and 
secondary fluorochrome Cy3-conjugated goat antibodies directed against rat IgG.  
Mouse monoclonal antibody specific for phosphorylated JNK (2 µg/ml, Santa Cruz), 
followed by secondary fluorochrome Cy3-conjugated goat antibody directed against 
mouse IgG (2 µg/ml, Dianova, Hamburg). 
A dendrite-specific mouse monoclonal antibody directed against microtubule associated 
protein-2 (MAP2, 2 µg/ml, Sigma) and secondary FITC-conjugated goat antibody 
directed against mouse IgG (2 µg/ml, Dianova, Hamburg). Baseline labeling was 
determined with mouse control antibodies and secondary fluorochrome Cy-3 conjugated 
goat antibodies directed against mouse IgG. 
Mouse monoclonal antibody specific for phosphorylated JNK (2 µg/ml, Santa Cruz), 
followed by secondary fluorochrome Cy3-conjugated goat antibody directed against 
mouse IgG (2 µg/ml, Dianova, Hamburg).  
   
 20
A dendrite-specific mouse monoclonal antibody directed against microtubule associated 
protein (TAU, 2 µg/ml, Sigma) and secondary FITC-conjugated goat antibody directed 
against mouse IgG (2 µg/ml, Dianova, Hamburg). Baseline labeling was determined with 
mouse control antibodies and secondary fluorochrome Cy-3 conjugated goat antibodies 
directed against mouse IgG. Optical sections along the z-axis were scanned with a 
confocal laser-scanning microscope (Leica, Nussloch,   Germany) equipped with a 63x or 
40x oil objective 
 
3.8 Lifetime based FRET analysis  
Hippocampal neurons were cultured for 5-10 days, fixed with 4% paraformaldehyde and 
then incubated with a mouse monoclonal antibody specific for KIF5B (1:200, Abcam), 
followed by secondary fluorochrome FITC-conjugated goat antibody directed against 
mouse IgG (1:400, Fab-fragments directed against Fab, Dianova). After washing, cells 
were incubated with a mouse monoclonal antibody directed against  β-tubulin III ( 1:400; 
Sigma) and secondary Cy3-conjugated goat antibody directed against mouse IgG (1:400; 
Fab-fragments directed against Fab, Dianova). As a negative control for the FRET 
analysis neurons were immunolabeled with mouse monoclonal antibody directed against 
KIF5B (1:200, Abcam), followed by secondary FITC-conjugated antibody directed 
against mouse IgG (1:400, Fab-fragments directed against Fab, Dianova). Then neurons 
were co-labeled with Cy3-conjugated mouse monoclonal antibody directed against 
neurofilament (1:400, Sigma). Classic confocal laser-scanning microscope (Leica) was 
performed with a 40x oil objective. Neurons were treated with 20 ng/ml TNF for 20 
minutes or pre-incubated for 5 minutes and co-treated with JNK inhibitor (SP600125; 
100 nM final) or TNF receptor I-IgG fusion protein (20 µg/ml; gift from Dr. Werner 
Lesslauer, Roche [62]) as indicated in the text and figures. 
Direct protein-protein interactions can be visualized via Föster Resonance Energy 
Transfer (FRET). FRET is a non-radiative, dipole coupling process, whereby energy from 
an exited donor (fluorophore) is transferred to an acceptor (fluorophore), which is in very 
close proximity. The efficiency of this process may be used to estimate the proximity of 
the two fluorophores [67]. Fluorescence Lifetime Imaging Microscopy (FLIM) is a 
technique suitable for studying protein interactions in space and time in fixed and living 
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samples through the detection of FRET [68]. Two-photon excitation allows the detection 
of photons from one focal plane, thus improving the signal-to-noise ratio of the acquired 
lifetime maps. We decided to use one of the most common FRET pairs (FITC//Cy3), well 
known for quantum efficiency and stability. All FLIM measurements were done with a 
63x oil or 40x oil  objective lens on a specific multi-photon microscopy system consisting 
of a time-domain FLIM setup (Becker-Hickl), an upgraded TSC-SP2 AOBS laser 
scanning confocal microscope (Leica Microsystems) and a Ti:Sapphire Mira900 two-
photon laser pumped by a Verdi-V8 laser (Coherent) in the mode-locked femtosecond-
pulsed regime. The laser was tuned to 900 nm for proper two photon excitation of FITC 
[69]. An emission filter wheel was placed between the output port of the scanning-head 
and the time domain-FLIM detector, an MCP-PMT (R3809U-50 by Hamamatsu 
Photonics). A 520 ±15 nm filter was used for FITC detection. The time-resolved 
fluorescence decays were reconstructed by time correlated single photon counting 
(TCSPC). The acquisition board (SPC830) and software (SPCImage) were from Becker 
& Hickl. The gate/rate that we obtained was between 103 to 104 photons/second with 
peak rates of 105 photons/second. Acquisition time was fixed to 900 seconds at an 
excitation power of 0.5-0.6 W. Using this system, 200 counts are required for a reliable 
mono-exponential decay fit and 1000 counts can give approximately 5% of statistical 
error in the lifetime estimations [70]. Lifetime images obtained were coded in 
pseudocolors with lifetime ranges of 1.0 to 1.9 nanoseconds in red (shorter lifetimes 
indicating FRET) and lifetime ranges of 1.9 to 4.0 nanoseconds in green (long lifetimes 
indicating NO FRET). Furthermore, lifetime values are presented as histograms. To 
quantify the percentage of axons showing a lifetime signal reflecting FRET, random 
images were analyzed. Neurons were treated with TNF (20 ng/ml for 20 minutes), TNF 
plus JNK inhibitor (SP600125; 100 nM) as indicated in the text and figures. 
 
3.9 The limits of the FRET system 
Whilst FRET measurements as a technique to define protein-protein interactions have 
been extant for many years, it is only recently that FRET measurements are being used as 
part of a standard repertoire of techniques for biology. Therefore, it is only now that 
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practical problems are being encountered. Thus, I think it is reasonable to describe my 
personal experience in using this system: 
It is impossible to have the perfect dyes for donor and acceptor: in theory they have to be 
photostable, have a high excitation coefficient, high quantum yield of emission, show 
small intensity fluctuations, introduce zero perturbance on the host and finally be 
commercial available. In addition it must be ideal for a FRET pair, large spectral 
separation, and comparable emission quantum yield for both donor and acceptor. We 
found that the FITC-Cy3 pair was sufficient for our purposes. In particular, we found that 
it was most important to have bright samples for imaging- we consistently saw that 
extending the imaging time for dim samples still produced much lower quality lifetime 
images than shorter exposures of bright samples, even if the numbers of collected 
photons were the same. 
 It is necessary to have a perfectly clean coverslip. These impurities give rise to 
fluorescence backgrounds, which contaminate lifetime measurements. In neuronal culture 
we can not use detergent, as even trace amounts can compromise the culture. We 
recommend extended washing of the coverslips. 
A most significant problem for biological assays is that labeling proteins with dyes in 
vivo significantly affect molecular reaction kinetics. In general, large fluorophores like 
GFPs can locally compromise the stability of the molecular reactions, or the functionality 
of proteins. Use of antibodies can avoid this problem, with the limit that this usually 
precludes in vivo FRET and of course strongly amplifies the problem of finding 
complimentary antibodies with proper orientation and distance. 
Photobleaching remains a problem for all XFP dyes. I found this to be especially true in 
my setup where use of the two photon and long time acquisition can badly compromise 
the experiment. Using antibodies, this situation changes and usually in normal conditions 
more than 105 photons can be detected, and this data can be acquired in relatively 
controlled way. 
Furthermore, use of GFP and mRFP can produce artifactual FRET: during the setup of 
the system, I constructed typical FRET pairs (Cerulean-YFP and EGFP-mRFP) in tandem 
by a short linker. In those cases, I obtained positive control values of 20-40% FRET. I 
was surprised to find that in negative controls, in cells doubly transfected with 
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cytoplasmic CMV-GFP and CMV-mRFP- the XFP proteins still physically interact. 
Using two techniques (acceptor photobleaching and by time-domain FLIM) I could show 
an artifactual value of FRET of about 5-10%. This phenomenon, if persistent can strongly 
compromise sensitive FRET experiments such as looking for single-pixel FRET, or 
screening when one looks for small values of FRET. I think in my case this error is 
avoided by using antibodies. 
Whilst the use of labeled secondary antibodies was the best solution for us, this system 
has not only positive aspects. It is very important to control for the risk of cross reaction 
between antibodies. In my case, where the staining was made by using 2 primary and 2 
secondary antibodies, it is clear how many degrees of freedom my system has. It took a 
very long time to establish the correct combination, which is very expensive not only in 
terms of time but in money as well. 
Another problem is that one always has to use the same set of antibodies, as even for 
monoclonal antibodies a change in lot number can drastically change the population of 
fretting molecules. In practical terms, for the 4 different antibodies one needs for such an 
experiment, one has to keep enough antibodies for perform all necessary experiments and 
controls. And finally, for me the most problematic difficulty is that this means that the 
repeatability of one’s experiment is strongly correlated with the availability of suitable 
antibodies. 
 
3.10 Immunprecipitation 
Protein was extracted from cultured hippocampal neurons by lysis buffer of cells either 
untreated or treated for 20 minutes by TNF (20 ng/ml). For immunoprecipitation cell 
lysates were incubated with either antibodies directed against β-tubulin III (2 µg / 
reaction; Sigma) or antibodies directed against KIF5B (2 µg / reaction; Abcam) at 4o for 
one hour. Subsequently, 20 µl of protein G sepharose beads (Amersham Biosciences, 
Freiburg, Germany) were added. The precipitated proteins as well as total protein lysates 
were analyzed by Western blotting with anti-β-tubulin III (Sigma). In a second step the 
membrane was re-blotted with anti-JNK antibodies (2 µg / reaction; Santa Cruz). 
Furthermore, protein lysates were precipitated by antibodies directed against  β-tubulin 
III (2 µg / reaction; Sigma) and protein G sepharose followed by Western blot analysis 
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with anti KIF5B and re-blotted anti-JNK antibodies (2 µg / reaction; Santa Cruz). 
Western blotting was performed with the NuPAGE electrophoresis system (Invitrogen) 
and the ECL Advance Western Blotting Detection Kit (Amersham Biosciences).  
 
 
3.11 Statistical analysis  
For statistical analysis t-test and Mann-Whitney U test were applied by SPSS software as 
indicated in the text and figures. Data of FRAP were analyzed by MatLab/Mathwork 
software and Excel Software (Microsoft). Statistical analysis of FRAP was performed 
using two-tailed t-test between the groups. 
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4. RESULTS 
4.1 Analysis of vesicle dynamics by FRAP  
Cultured hippocampal neurons derived from embryonic mice were transfected with 
synaptophysin-EGFP under control of the synapsin I promoter to achieve near-
physiological levels of expression. The neurons were used for experiments at day 5-10, 
when the EGFP signal was mainly localized in the axon as showed in 
immunohistochemistry samples, Fig. 2.  
Confocal laser scanning microscopy of synaptophysin-EGFP in living neurons 
demonstrated that individual small vesicle-like structures were moving along the axon. 
However, the movements could not sufficiently be followed over long distances and 
separated from the immobile synaptophysin-EGFP structures. 
In order to measure the axonal motility of synaptophysin-EGFP, we adopted the 
fluorescence recovery after photobleaching (FRAP) technique, which is widely used to 
determine the diffusion of fluorescent molecules in living cells. A 20 µm long segment of 
the axon was bleached with high laser intensity and recovery of the fluorescence signal 
over time was measured with low laser power each 10-60 seconds (Fig. 2). The motility 
of axonally transported synaptophysin-EGFP is dependent on the mobile fraction of 
transported synaptophysin and the half-time value t½ of the fluorescence recovery curve, 
which is inversely proportional to the velocity of the transported synaptophysin-EGFP. 
The half-time value t½ of the fluorescence recovery after photobleaching (FRAP) was 
determined from the equation of the measured fluorescence intensity over time. The 
relation of mobile synaptophysin-EGFP compared to immobile synaptophysin was 
determined from the pre-bleaching fluorescence intensity and the calculated maximum of 
fluorescence recovery, Fig. 2d. 
First, neurons were transfected with EGFP alone, which has been shown to freely diffuse 
within the cytoplasm. Then, a 20 µm long segment of the axon was bleached. Within 1-2 
seconds, the bleached axonal segment was completely filled up by EGFP confirming 
rapid and free diffusion of EGFP. Next, neurons were transfected with synaptophysin-
EGFP, which has been shown to be integrated as a membrane molecule in synaptic 
vesicle precursors [64]. Fluorescence recovery of the synaptophysin-EGFP signal after 
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bleaching was relatively slow and lasted more than 600 seconds, Fig. 2d. The 
synaptophysin-EGFP filled up the bleached axon preferentially from the proximal side, 
indicating that synaptophysin-EGFP was mainly transported anterogradely.  
 
4.2 Microglia culture and activation 
Neuropathological data suggested a correlation between axonal transport disturbance and 
activated microglial cells. Therefore, we asked whether microglial cells stimulated to 
release inflammatory mediators might affect the axonal transport of synaptophysin. 
Microglial cells were isolated from mixed glial culture derived from postnatal mouse 
brain tissue. Flow cytometry analysis revealed that 96.1% (+/-7 % SD) of isolated cells 
expressed the microglial marker CD11b/CD18 on the cell (data not shown). Microglial 
was stimulated by combined treatment with the proinflammatory cytokines interferon-
gamma and interleukin-1β for 72 hours, and showed the characteristic morphologies of 
activated microglia (data not shown ).  
The cytokine-stimulated microglial cells were labeled with a vital cell membrane red 
fluorescence dye and added to cultured hippocampal neurons transfected with 
synaptophysin-EGFP. The microglial cells appeared to bind to axons within a few 
minutes, Fig. 3.  
 
4.3 Mimicking  the effect of nitric oxide (NO) and study vesicle transport 
To mimic the effect of reactive nitric oxide (NO) released by microglia, we added a short 
term NO donor (DEA/NONOate) to the cultured neurons and measured the recovery of 
the fluorescence signal after photobleaching of synaptophysin-EGFP. DEA/NONOate is 
known to release reactive NO within a few minutes (half-life of 2.1 minutes) under the 
performed analysis conditions (at 37°C in aqueous solution at physiological pH) [71].  
The half-time value t½ of the FRAP, which is inversely proportional to the velocity of 
synaptophysin-EGFP, was unchanged at 5-10 minutes after NO donor treatment and only 
slightly increased after 30 minutes of NO donor treatment, Fig. 4. After 120 minutes 
treatment with 300 µM DEA/NONOate, the value returned back to levels comparable to 
untreated neurons. This demonstrates that the speed of mobile vesicles is largely 
unaffected by treatment with NO. Detailed analysis demonstrated that there was a 
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significant decrease in the portion of mobile particles (mobile fraction) of synaptophysin-
EGFP after treatment with NO, indicating that NO reduced the percentage of 
synaptophysin-EGFP transported along the axon. The mobile fraction of synaptophysin-
EGFP decreased from 0.65 +/- 0.18 SD to 0.29 +/- 0.07 SD after 5 minutes treatment 
with 300 µM DEA/NONOate, Fig 4c.  
Two major routes of NO signaling in neurons are known, the cGMP signaling pathway 
and S-nitrosylation of proteins [72]. To analyze whether stimulation of cGMP might 
modulate motility of synaptophysin-EGFP, we treated neurons with 8-Bromo-cGMP, a 
membrane-permeant analogue of cGMP. Treatment with 0.2 mM 8-Bromo-cGMP for 5-
10 minutes or 30-35 minutes did not modulate axonal motility of synaptophysin-EGFP, 
Fig. 4. Furthermore, blocking endogenous neuronal NOS with high concentrations of the 
inhibitor aminoguanidine (2 mM) did not affect axonal motility of synaptophysin-EGFP, 
Fig. 4.  
 
4.4 Phosphorylation JNK after treatment with NO 
Nitric oxide has been shown to positively stimulate c-Jun N-terminal kinase/stress-
activated protein kinase (JNK) in endothelial cells [73], cardiomyocytes [74] and 
negatively regulate JNK in interferon-gamma stimulated macrophages by means of S-
nitrosylation [75]. Furthermore, it has been suggested that JNK is a possible modulator of 
kinesin-mediated axonal transport [13, 76].  
First, phosphorylation of JNK in axons was studied after treatment with NO donor. 
Immunolabeling of the phosphorylated form of JNK was performed with a specific 
monoclonal antibody in neurons transfected with synaptophysin-EGFP. While untreated 
neurons showed no or very low fluorescence signal for phosphorylated JNK in neurites, 
neurons treated for 10 minutes with 300 µM DEA/NONOate and identified by double-
labeling with antibodies directed against the axon protein microtubule associated protein  
(Tau) showed intense labeling of axons, Fig. 6. 
Phosphorylation of the all three JNK family members (JNK-1, JNK-2 and JNK-3) was 
blocked with the inhibitor SP600125 JNK Inhibitor II (concentration 100 nM) in the 
neuronal cultures.  
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4.5 Effect of JNK-inhibitor on movement of synaptophysin-EGFP 
Interestingly, pre-treatment of neurons with the JNK inhibitor neutralized the effect of 
NO donor and TNF-α on axonal motility of synaptophysin-EGFP.  
The neurons were pre-incubated for at least 30 min with 100 nM JNK inhibitor II. The 
inhibitor alone did not influence the motility and transport of synaptophysin-EGFP as 
determined by FRAP, Fig. 5, and by the cross-correlation analysis (From Petra Dietrich, 
data not shown). Then, the NO donor was added to neurons pre-treated with the JNK 
inhibitor and cross-correlation data were recorded at the same position in the axon. The 
JNK inhibitor prevented the effect of NO on axonal motility of synaptophysin-EGFP, 
Fig. 5. The same results were obtained when repeating these experiments by tracking 
synaptotagmin-EGFP, Fig. 7. 
 
4.6 Expression of TNF receptors on axons of cultured hippocampal neurons 
Hippocampal neurons cultured for 5-8 days were analyzed for expression of tumor TNF 
receptors by immunofluorescence labeling. Neurons were labeled with antibodies 
directed against TNF receptor I or TNF receptor II. Double-labeling was performed by 
monoclonal mouse antibodies directed against the axonal marker protein tau. Analysis by 
confocal microscopy demonstrated that the majority of axons identified by staining with 
tau showed immunostaining for TNF receptor I and II, Fig. 8. In total, 50% +/- 10 % 
(mean +/- SD) of axons were labeled with antibodies against TNF receptor I and 40 % +/- 
20 % of axons were labeled with antibodies directed against TNF receptor II, Fig. 8. 
 
4.7 Phosphorylated JNK in axons after treatment with TNF 
Phosphorylation of JNK is the result of the inflammatory cytokine TNF signaling in most 
cell types. Therefore, we analyzed phosphorylation of JNK in axons after treatment of 
neurons with TNF-α. Cultured hippocampal neurons were treated with TNF-α (20 ng/ml) 
for 20 minutes and activity of JNK was analyzed by immunohistochemistry with specific 
antibodies directed against phosphorylated JNK. Axons were identified by double 
labeling with antibodies directed against tau. In untreated neurons phosphorylated JNK 
was detected in neuronal cell bodies, but not in axons, Fig. 9a. After treatment of neurons 
with TNF-α, strong immunolabeling of axons with specific antibodies directed against 
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phosphorylated JNK was detected by confocal microscopy, Fig. 9b. Quantification of tau 
positive axons showed that almost all treated axons (84 %   +/- 13%; mean +/- SD) 
expressed phosphorylated JNK, while in untreated neurons a minority of axons (11 % +/- 
7%) showed immunolabeling for phosphorylated JNK, Fig. 9c. 
  
4.8 Association between KIF5B, β-tubulin-III and JNK 
Recently, molecular interaction was observed between JNK, JNK-interacting protein 3 
(JIP3) and kinesin-1 [77]. Therefore, we performed co-immunoprecipitation to analyze 
whether JNK forms a complex together with the motor protein kinesin heavy chain 
isoform KIF5B. Protein lysates were obtained from cultured hippocampal neurons and 
immunoprecipitated with antibodies directed against β-tubulin-III or KIF5B. 
Immunodetection after Western blotting demonstrated that JNK precipitated together 
with β-tubulin-III and KIF5B, Fig. 9d. Thus, immunoprecipitation indicated that JNK 
forms a complex together with KIF5B and β-tubulin-III. No difference in the amount of 
JNK or KIF5B bound to β-tubulin-III  in immunoprecipitated lysates derived from whole 
cell cultures was detected after treatment of neurons with TNF (20 ng/ml) for 20 minutes, 
Fig. 9e. 
  
4.9 Dissociation of KIF5b from β-tubulin-III after TNF treatment in axons 
Since JNK, KIF5B and β-tubulin-III formed a complex and TNF-α treatment induced 
phosphorylation of JNK in axons, we analyzed the effect of TNF-α on the molecular 
interaction between KIF5B and β-tubulin-III at a subcellular level. Lifetime-based 
Förster resonance energy transfer (FRET) analysis was performed to allow subcellular 
localization of the molecular interaction between KIF5B and β-tubulin-III. Cultured 
hippocampal neurons were double-immunolabeled with monoclonal antibodies directed 
against KIF5B marked with the fluorophore FITC (KIF5B-FITC) and monoclonal 
antibodies directed against β-tubulin-III marked with the fluorophore Cy3 (β-tubulin-III-
Cy3). As a negative control, neurons were double-immunolabeled with monoclonal 
antibodies KIF5B-FITC and monoclonal antibodies directed against neuroflilament 
marked with fluorophore Cy3 (neurofilament-Cy3). Furthermore, neurons were solely 
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labeled with antibodies KIF5B-FITC to determine the regular lifetime as a control. First, 
confocal fluorescence intensity based images were obtained showing co-localization of 
KIF5B and β-tubulin-III in axons irrespective of TNF-α and JNK inhibitor treatment, Fig. 
10. 
Second, fluorescence lifetime images were obtained from KIF5B-FITC by two-photon 
excitation and time correlated single photon counting. An emission filter for KIF5B-FITC 
detection was placed between the output port of the scanning-head and the time domain 
fluorescence lifetime imaging detector. Lifetimes from 1.0 to 1.9 nanoseconds were 
coded in red, representing expected signals from FRET, Fig. 11. Lifetimes from 1.9 to 4.0 
nanoseconds were coded in green, representing the expected lifetime of KIF5B-FITC in 
the absence of acceptor, Fig. 11. 
Both the lifetime of KIF5B-FITC in the absence of acceptor or in the presence of an 
irrelevant acceptor (neurofilament-Cy3) showed a normal distribution with 2.2 +/- 0.13 
nanoseconds (mean +/- SD) and 2.25 +/- 0.14 nanoseconds, indicative of a lack of FRET, 
Fig. 12. A strong FRET interaction was observed in untreated neurons co-labeled with β-
tubulin-III-Cy3 and KIF5B-FITC showing a shifted distribution towards shorter lifetimes 
with a peak value of 1.5 +/- 0.18 nanoseconds Fig. 12b. Pre-treatment with TNF-α for 20 
minutes abolished the FRET interaction specifically in axons, but not cell bodies, 
allowing us to recover lifetimes similar to negative controls, Fig. 11b.  
To quantify the effect of TNF-α on the interaction between KIF5B-FITC and β-tubulin-
III-Cy3 we determined the average of the peak lifetimes collected from several regions of 
interest in the axons, Fig. 12b. In detail, the averaged peak lifetime value in axons was 
2.3 +/- 0.5 nanoseconds (mean +/- SD) after 20 minutes TNF-α treatment, while in 
untreated axons the averaged peak lifetime was 1.5 +/- 0.18 nanoseconds, Fig. 12b. Thus, 
treatment of hippocampal neurons with TNF-α broke apart the molecular interaction 
between KIF5B and β-tubulin-III in axons (Fig. 3b). To determine whether the 
interaction between KIF5B-FITC and β-tubulin-III-Cy3 in the axons of all cells was 
affected by TNF-α, we analyzed the percentage of axons displaying lifetimes lower than 
1.9 nanoseconds. In detail, in untreated neurons 93 +/- 27 % (mean +/- SD) of axons 
showed shorter lifetimes compatible with FRET, while in TNF treated neurons the 
percentage of axons showing FRET between KIF5B-FITC and β-tubulin-III-Cy3 was 
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reduced to 4 +/- 19 % (Fig. 4c). No FRET was observed in the controls by co-labeling 
KIF5B-FITC and neurofilament-Cy3 of by imaging KIF5B-FITC in the absence of 
acceptors, Fig. 12. 
 
4.10 Involvement of JNK phosphorylation in dissociation of KIF5B and β-tubulin-
III 
We then analyzed the involvement of JNK phosphorylation in TNF-α induced breakage 
of the molecular interaction between KIF5B and β-tubulin-III. Hippocampal neurons 
were treated with TNF-α for 20 minutes and additionally JNK was blocked with the JNK 
inhibitor SP600125. Cells were co-labeled for KIF5B-FITC and β-tubulin-III-Cy3. Both 
confocal fluorescence intensity, Fig. 10 and lifetime images were obtained, Fig. 11c. 
Additional treatment with the JNK inhibitor reduced the effect of TNF on the molecular 
interaction between KIF5B and β-tubulin-III, Fig. 11 and 11. After JNK inhibitor 
application, the mean lifetime value of KIF5B-FITC of TNF treated neurons was 1.76 +/- 
0.15 nanoseconds (mean +/- SD) compared to 1.5 +/- 0.18 nanoseconds in neurons 
treated with TNF-α alone, Fig. 12. After inhibition of JNK, low lifetimes were again 
detected in 60 +/- 19% (mean +/- SD) of axons of TNF-α plus JNK inhibitor treated 
neurons, while reduced lifetimes were observed in 4 +/- 19 % of axons in neurons treated 
with TNF-α alone, Fig. 12. 
 
4.11 Inhibition of axonal mitochondrial transport by TNF-α via JNK 
phosphorylation 
The motor protein KIF5B has been shown to be essential for axonal mitochondrial 
transport [78]. To study whether TNF-α disturbs axonal transport of mitochondria, we 
transfected cultured hippocampal neurons with a mitochondrial targeting sequence tagged 
with enhanced yellow fluorescent protein (YFP). To achieve low levels of expression we 
expressed this mitochondria marker under a neuron-specific synapsin I promoter. The 
neurons showed expression of YFP in mitochondria starting from day 2-3 in culture and 
normal axonal morphology, comparable to untransfected neurons. The YFP signal was 
specifically localized in structures typical of mitochondria, Fig. 13a. Transfected cultures 
were placed in a heated chamber and scanned every 20 seconds by confocal microscopy. 
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Mitochondria showed anterograde and retrograde movement in axons, which are 
illustrated in the corresponding kymographs, Fig. 13a. To analyze the movement of 
mitochondria, we determined the number of moving mitochondria (mobile fraction) and 
their velocity. In total 20 +/- 12 % (mean +/- SD) of mitochondria moved anterogradely 
and 21 +/- 17 % retrogradely. After treatment with TNF-α for 20 minutes, mitochondria 
stopped moving. In total, the mobile fraction of mitochondria decreased from 41 +/- 14 % 
to 7 +/- 4 % after treatment with TNF-α for 20 minutes. Both anterograde and retrograde 
movements were substantially reduced to 3 +/- 4 % and  4 +/- 4 %, respectively, Fig. 13b. 
No change in the velocity in the remaining mobile mitochondria was observed after TNF-
α treatment. Mitochondria moved anterogradely with a velocity of 0.39 +/- 0.15 µm/sec 
(mean +/- SD) and retrogradely with a velocity of 0.39 +/- 0.19 µm/sec in untreated. 
neurons. In neurons treated with TNF-α for 20 mins, they traveled anterogradely with a 
velocity of 0.36 +/- 0.17 µm/sec and retrogradely with a velocity of 0.35 +/- 0.19 µm/sec, 
Fig. 12c. Inhibition of axonal transport by TNF was mediated via JNK phosphorylation. 
In detail, after co-treatment of neurons with TNF-α for 20 minutes and the generalized 
JNK inhibitor 45 +/- 9 % of mitochondria were mobile, very similar to the untreated 
situation, in which 41 +/- 14 % of mitochondria were mobile. Both anterograde and 
retrograde movements were regained in TNF treated axons after JNK inhibition to 23 +/- 
10 % and 22 +/- 12 % respectively, Fig. 13b. The inhibitory effect of TNF-α on axonal 
movement of mitochondria was not long lasting. Already 360 minutes after treatment 
with TNF-α, axons again showed an increased percentage of moving mitochondria, Fig. 
13b. 
 
4.12 Inhibition of axonal synaptophysin transport by TNF-α via JNK 
phosphorylation 
To study whether TNF-α inhibits synaptophysin transport in axons, we transfected 
cultured hippocampal neurons with synaptophysin tagged with GFP and performed 
FRAP analysis of a 20 µm long axonal segment, Fig. 14a. The mobile fraction and the 
half-time value t ½ of the fluorescence recovery curve were determined as characteristics 
of the movement. At 20 minutes and 30 minutes after treatment of neurons with TNF-α, a 
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significant reduction in the axonal transport of synaptophysin-GFP was detected as 
determined by FRAP, Fig. 14. In detail, the relative FRAP intensity at 300 seconds was 
reduced from 0.32 +/- 0.14 (mean +/- SD) to 0.11 +/- 0.04 after 20 minutes treatment 
with TNF- α Fig. 14b. At 360 minutes after treatment with TNF-α, the value returned 
back to levels comparable to untreated neurons. Furthermore, there was a significant 
decrease in the mobile fraction of synaptophysin-GFP after treatment with TNF-α, 
indicating that TNF-α reduced the percentage of synaptophysin-GFP transported along 
the axon. The mobile fraction of synaptophysin-GFP decreased from 39 +/- 14% (mean 
+/- SD) to 13 +/- 4% after 20 minutes treatment with TNF-α, Fig. 14c. The half-time 
value t½ of the FRAP, which is correlated to the velocity of synaptophysin-EGFP, was 
unchanged and not modulated by TNF-α treatment, Fig. 14d. Inhibition of JNK 
completely neutralized the effect of TNF-α on axonal movement of synaptophysin-GFP. 
Blockade of JNK in TNF-α treated axons resulted in a mobile fraction of 46 +/- 21%, 
while axons treated with TNF-α alone showed a mobile fraction of synaptophysin-GFP of 
13 +/- 4%, Fig. 14c. 
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5. DISCUSSION 
5.1 Analysis of directed movement with FRAP method 
Novel biophysical techniques were applied to study the motility of synaptophysin-EGFP 
and synaptotagmin I-EGFP in axons. The FRAP method is based on measurement of the 
net increase in fluorescence signal of a bleached segment.  
Detailed analysis of  FRAP showed that in unchallenged axons, approximately 30-40% of 
the labeled vesicle precursors are immobile either due to directed motion ceasing or 
formation of presynaptic-like structures. The NO donor and TNF-α had a major effect on 
the immobile fraction, which increased up to 80 %, while the effect on t ½ reflecting the 
velocity of the movement was not significantly changed after 5-10 minutes of NO donor 
or TNF-α treatment. These data clearly demonstrate that these cytokines inhibit the net 
movement of labeled vesicle precursors by increasing the number of immobile particles. 
 
5.2 Effects of microglia/NO/ TNF-α on neurites 
Microglial cells are activated and highly motile in inflammatory and degenerative brain 
diseases. In pathological situations they directly interact with neurons and could bind and 
ensheathe naked or demyelinated axons [4, 79, 80]  in cerebral ischemia. In this study, 
NO produced by microglia is capable of inhibiting axonal motility of synaptophysin-
EGFP. It is tempting to speculate that prolonged blockade of axonal transport by NO 
might injure the axon and induce degeneration although in this study we used a donor 
which gives a short-term pulse of NO, rather than a promulgated release of NO. 
Nitric oxide (NO) is produced in the brain by three isoforms of NO synthase, neuronal 
(nNOS, type I), endothelial (eNOS, type III) and inducible (iNOS, type II). Nitric oxide 
participates in diverse physiological brain processes including brain development, pain 
perception, neuronal plasticity, memory and behavior [81-84]. Furthermore, NO donors 
added to recombinant synaptic proteins blocked the interaction of n-sec1 with syntaxin 
1a, while it promoted that of VAMP/SNAP-25/syntaxin 1a through induction of disulfide 
linkages [85], indicating the importance of this molecule in regulating fine processes in 
the vesicle cycle. 
In this study, no evidence for involvement of neuronal NOS in modulation of axonal 
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transport was observed. Treatment of neurons with high concentrations of 
aminoguanidine (2 mM), Fig. 4, which inhibits both iNOS and nNOS, did not modulate 
the relative FRAP or mobile/immobile fraction. However, this study concentrated on 
axonal locations and it cannot be excluded that nNOS acts at the presynaptic site, its 
major location, on transport of synaptic vesicle precursors. While we showed a 
pathologic action of NO released by activated microglia, one can speculate that NO 
derived from nNOS might act under physiological situations at the axonal terminal to 
detach synaptophysin containing precursor vesicles from the motor protein KIF1a or 
tubulin. 
TNF is preferentially produced by activated glial cells, microglia, and astrocytes during 
brain injury or inflammatory processes [86]. For instance, TNF-α protein has been 
localized in glial cells after experimental autoimmune encephalomyelitis [87]. 
TNF-α protein was also detected in neurons by immunohistochemistry after mechanical 
[88] or ischemic brain injury [89]. Furthermore, TNF-α gene transcription and protein 
production have been observed during development in total brain tissue extracts [89]. In 
culture, astrocytes secrete TNF-α at low levels, but cytokine secretion is strongly 
increased after treatment with inflammatory stimuli such as IFN-gamma combined with 
IL-β 1 [90]. TNF-α is produced as a propeptide, which integrates into the cell membrane 
as a stable homotrimer or can be clipped off at the transmembrane domain by the 
metalloproteinase TNF-α converting enzyme TACE, [91]. The biological activity of 
TNF-α is mediated via either the TNFRI (p55 TNF receptor, CD120a) or the TNFRII 
(p75 TNF receptor, CD120b), which have overlapping functions.  
In this study, TNF-α stimulated phosphorylation of JNK in axons.  Reduced motility of 
synaptophysin-EGFP and synaptotagmin-EGFP after TNF-α treatment was dependent on 
phosphorylation of JNK as determined by the JNK inhibitor SP600125.  
 
5.3 Mitochondrial tracking 
Unlike the vesicle precursors labeled by synaptophysin-EGFP and synaptotagmin I-
EGFP, which are widely supposed to be transported by the KIF1A, multiple strands of 
evidence suggest that mitochondrial movement is mediated by KIF5B [78]. 
To study whether the acute impairment of axonal transport after exposure to 
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inflammatory mediators is a general phenomenon, individual mitochondria were 
genetically labeled and tracked in living axons. Here, as one can clearly identify 
individual mitochondria, the velocity of these particles could be directly measured, whilst 
collecting data on mobile and immobile fractions. 
We found that mitochondrial transport was affected in an identical manner to synaptic 
vesicle precursor transport. In unchallenged neurons, approximately 60% of mitochondria 
are immobile (Fig. 14). Within five minutes of exposure to TNF-α, this number increases 
to 93% of all mitochondria. This effect is transient, possibly as the culture can metabolize 
TNF-α, so that 6 hours after exposure to TNF-α, normal levels of transport are restored 
(Fig. 14).  
The acute effect of TNF-α at five minutes of exposure can be blocked by pre-incubating 
neuronal cultures with decoy receptor, indicating the effect´s specificity for TNF-α. 
Consistent with the experiments performed with labeled synaptic vesicle precursors, the 
effect of TNF-α on mitochondrial transport was blocked by pre-incubation of culture with 
the JNK inhibitor (Fig.  13). 
Also in this experiment, the velocity of the remaining mobile cargo is unchanged (Fig. 
15). Intriguingly, both anterograde and retrograde transport is inhibited by TNF-α in a 
JNK-dependent manner. Whilst we and others have some concrete evidence linking JNK 
signaling to kinesin scaffolds,  much less is known about dynein (which is the canonical 
retrograde motor) and its adaptor proteins [50]. However recent evidence links the JIP 
scaffold proteins to the dynein motor protein as well [76]. It is tempting to speculate that 
a similar mechanism is also at play for retrograde transport, and that transient transport 
stoppage is a common response to an inflammatory milleu. 
We then wished to investigate the molecular mechanism in more detail. It is known that 
TNF-α can induce changes in cytoskeletal structures [92]. It is suggested that the 
stimulation of apoptosis by cytoskeletal inhibitors may be attributed to the altered 
distribution of cell organelles, especially mitochondria. [92]. 
However, as we observed that the velocity of moving cargoes remained constant in all of 
our experiments, we found it unlikely that the microtubulae were modified by TNF-α (or 
indeed, NO) exposure on a short timescale. Rather, we believe that the motor protein, or 
its cargo, is directly modulated by JNK signaling stimulated by inflammation.  
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5.4 Molecular mechanism, JNK 
To look at conformational changes in the kinesin-microtubule complex directly, we 
employed the FRET technique in neurons. 
Our results allow several crucial insights into the mechanisms regulating axonal 
transport. First, we demonstrate that TNF-α breaks apart the molecular interaction 
between KIF5B and tubulin via JNK phosphorylation selectively in axons, but not cell 
bodies. Thus, JNK not only forms a complex with kinesin and JIP, but also appears to 
directly modulate the function of kinesin. Second, our data show that TNF-α inhibits 
anterograde and retrograde axonal movement of mitochondria via JNK phosphorylation. 
Third, we demonstrate that TNF-α impairs axonal movement of synaptophysin via JNK 
phosphorylation. Thus, JNK-mediated effects on the kinesin-tubulin complex after TNF-
α application has important functional consequences leading to impairment in axonal 
transport of mitochondria and synaptic vesicle precursors. 
Primarily, JNKs have been suggested to sense axonal injury and participate in the 
initiation of the axonal injury response [50]. JNKs are rapidly activated within the axons 
following nerve injury and can be transported on microtubules along the axon via their 
association with motor proteins of the kinesin family [50].  
The JNK pathway would therefore be an attractive candidate as a sensor of the axonal 
injury response and regulator of axonal transport [76]. Furthermore, activation of JNK 
along the length of the axon has also been reported in a mouse model of type-I diabetes, 
probably representing a danger-signaling system for nerves [95]. In the case of 
mechanical damage occurring upon nerve injury, JNK was locally phosphorylated at the 
site of injury [96] and retrograde signals involving JNK support nerve survival and 
regeneration [97, 98]. In addition, JNK may have downstream axoplasmic substrates and 
play an active role in cytoskeletal function. Particularly, JNK1 phosphoryated the 
microtubule-associated protein 2 [99] and was a dominant regulator of the dendritic 
architecture [100]. In this study we concentrated on the axon and demonstrated that JNK 
activation has local axonal effects on the motor machinery in response to the pro-
inflammatory cytokine TNF-α. Our data suggest that JNK acts on the motor machinery, 
but not on the axonal cytoskeleton since the velocity of the mitochondria and 
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synaptophysin remaining motile was not altered after JNK stimulation via TNF-α 
treatment. 
JNKs are linked to the kinesin motor proteins via JIPs. Two approaches led to the 
discovery of the JIPs as kinesin-binding proteins. Bowman et al. [48] performed a genetic 
screen in Drosophila and identified JIP3 (Sunday Driver, SYD) as interactor of kinesin. 
Verhey et al. [50] identified JIP1, JIP2 and JIP3 as kinesin protein binding partners by 
co-immunoprecipitation. The indirect linkage of motors, JNK and cargo via the JIP 
scaffolding proteins would allow JNK to act as signal transducers to regulate motor 
activity. Principally, JNK kinases might phosphorylate either kinesin itself or an 
associated protein, thereby inactivating the motor and leading to dissociation of kinesin 
from tubulin. We now demonstrated that lifetime-based FRET analysis can be applied in 
primary neurons to analyze the interaction between tubulin and motor proteins on a 
subcellular level [56]. Particularly, alterations of the kinesin-tubulin complex after TNF-α 
treatment were observed in the axons, but not in the cell bodies. Therefore, classical 
techniques such as immunoprecipitation are not ideally suited to study these interactions. 
Likewise, we failed to see a clear effect of TNF-α in immunoprecipitation on the 
molecular interaction between tubulin and kinesin. Principally, the FRET data are 
consistent with either a change in the conformation of the kinesin-tubulin complex or a 
complete detachment of kinesin from the microtubules. However, the characteristic 
increase in the immobile fraction without interference in the velocity of the remaining 
mobile particles indicates that the kinesin complex dissociates from the microtubules. 
Particularly, immobile kinesin, which would bind in an ‘off’ confirmation to tubulin, 
would act as an obstacle for the remaining mobile particles leading to reduced velocity. 
As this is not the case, it is indicative that the path of moving mitochondria and 
synaptophysin is not obstructed at all and immobile mitochondria and synaptophysin 
containing precursor vesicles are likely to dissociate from tubulin after JNK stimulation 
by TNF-α.  
Previously, it was shown that TNF-α induced perinuclear clustering of mitochondria in 
fibroblasts via the TNF receptor I [101]. It was suggested that TNF-α acted via 
hyperphosphorylation of kinesin light chain and inhibited the kinesin-mediated transport 
of mitochondria [102]. Thus, TNF-α appears to act on the kinesin motor complex in 
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several cell types. Perinuclear clustering of mitochondria was also evident in mice with 
targeted disruption of the conventional kinesin heavy chain KIF5B [78]. The 
mitochondrial dislocation was reversed by exogenous expression of KIF5B [78] 
indicating that KIF5B is required for plus end-directed transport of mitochondria along 
microtubules. Our data now link mitochondrial movement and conformational change in 
KIF5B via TNF-α -induced JNK phosphorylation. Furthermore, we demonstrated that 
TNF-α-induced JNK phosphorylation inhibits synaptophysin transport. Synaptophysin is 
produced at the cell body, integrated into synaptic vesicle precursors and then 
anterogradely transported along axons [103]. Defects in axonal transport of 
synaptophysin containing vesicle precursors have been observed in KIF1A mutant mice. 
Thus, the JNK signaling pathway appears to be widely involved in axonal transport of 
organelles and vesicular structures. 
Very little is known about the regulation of vesicle transport and detachment of vesicles 
from tubulin in axons. Synaptic precursor vesicles containing synaptophysin are 
connected to the kinesin motor protein KIF1a via scaffolding proteins of the JSAP1/JIP3 
family [49]. The JIP family associates with JNK and JNK kinases, which appear to be 
responsible for the regulation of the vesicle movement by modulating the attachment and 
detachment of the vesicle to the kinesin motors [49]. In principal both NO and TNF-α 
could directly act on the JNK or JNK kinases, which have been shown to be modulated 
by S-nitrosylation [104]. In case of NO it might also act on the kinesin motors, which 
have essential cysteins at their binding sites to tubulin. However, NO treated neurons 
inhibited by JNK were again wild-type suggesting NO acts indirectly on kinesin motor 
protein via JNK. 
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6. CONCLUSION 
The data demonstrate that NO and TNF-α released by activated microglia inhibit directed 
axonal movement of synaptic precursor vesicles containing synaptophysin or 
synaptotagmin I. In a collaborating laboratory, this data was confirmed by directly 
measuring the velocity of labeled precursors using the FCS (fluorescence correlation 
spectroscopy) technique. In these experiments, labeled precursors traveled at velocities 
well comparable with published values, and the fraction of immobile vesicles was 
strongly increased by treatment with NO. 
This data was also confirmed by mitochondrial tracking experiments, where we clearly 
demonstrate that TNF α transiently but strongly impaired the transport of mitochondria 
and that this phenomenon is mediated via the JNK pathway. Interestingly, the velocity of 
these cargoes was not affected by TNF-α treatment.   This suggests the protein complexes 
driving the vesicle are dynamically regulated by signal transduction pathways with a 
common nexus over the JNK protein. 
We demonstrate that JNK is associated with a complex containing β III tubulin and the 
motor protein KIF5B. Finally, FRET experiments showed that the direct interaction 
between conventional kinesin KIF5b and β III tubulin is abrogated by exposure to TNF-
α, and that it could be restored by pre-inhibition of JNK signalling. 
These results allow us to construct a model, where JNK incorporated in the scaffold of 
motor proteins causes the detachment of the motor protein from tubulin upon exposure to 
an inflammatory signaling. Those motor proteins unaffected by active JNK are thus able 
to be transported at normal velocities. 
Another implication raised by our model is that now we began to understand the fine and 
complex link between inflammation (particularly activated microglia) and neuronal 
axonal transport, suggesting a future point for therapeutical intervention.  
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Fig 1. NO release by cytokine-stimulated microglia. (a) Measurement of NO released in the supernatant of 
cultured microglia at distinct time periods after combined cytokine (10 ng/ml IL-1β and 100 U/ml IFN-γ 
for 72 hours) stimulation. To measure the release of NO from microglial cells the Griess Reagent System 
(Promega) was used. The system was calibrated with a standard curve. The detection limit was 2.5 µM 
nitrite. (b) Detection of inducible NO synthase (iNOS) gene transcripts in microglia stimulated by the 
cytokines IFN-γ (100 U/ml) and IL-1β (10 ng/ml) for 72 hours. Gene transcripts for GAPDH were 
amplified by RTPCR as control. RT-PCR was performed by 30 cycles of amplification with the following 
primers for iNOS, TNF-alpha and GAPDH: iNOS ( 5'-AAGCTGCATGTGACATCGAC-3' ; 5'-
TGCTGAAACATTTCCTGTGC-3' ) , TNF ( 5-GGGGTGATCGGTCCCCAAAGG-3 ; 5-
CGGGGCAGCCTTGTCCCTTG-3 ) ; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ( 5'-
TCCGCCCCTTCTGCCGATG-3' ; 5'- CACGGAAGGCCATGCCAGTGA-3’ ). 
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Fig 2. Axonal expression and FRAP analysis of synaptophysin-EGFP. a, Neuron transfected with 
synaptophysin-EGFP (green) and immunolabeled with antibodies directed against tau (red). 
Synaptophysin-EGFP is localized in the axon. Area selected for inset as indicated. Scale bar, 10 m. b, 
Neuron transfected with synaptophysin-EGFP (green) and immunolabeled with an antibody directed 
against VAMP2 (red). Colocalization between synaptophysin-EGFP and VAMP2 demonstrates expression 
of synaptophysin-EGFP in synaptic vesicle precursors. Area selected for inset as indicated. Scale bar, 10 m. 
c, FRAP of an axon from a synaptophysin-EGFP-transfected neuron. The bleached area of 20 min length 
(white circle) was scanned by confocal microscopy over time, and fluorescence recovery intensity was 
determined. Selected images before bleaching and 120, 240, 360, 480, and 600 sec after bleaching are 
shown. Scale bar, 10 m. d, Relative FRAP intensity of synaptophysin-EGFP in an axon that was time-lapse 
scanned over 1200 sec. Individual values of each 10 sec and the curve of the equation are shown. 
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Fig 3. Impaired axonal movement of synaptophysin-EGFP near cytokine-stimulated microglia. a, Cultured 
hippocampal neurons were transfected with synaptophysin-EGFP. Axon of a neuron transfected with 
synaptophysin-EGFP (green) and challenged with cytokine-stimulated microglia (red) is shown. Area of 
FRAP analysis as indicated. Scale bar, 20 m. b, Fluorescence and transmission images from an axon of a 
neuron transfected with synaptophysin-EGFP (green) and challenged with a cytokine-stimulated microglia 
(see area of FRAP analysis in A). Fluorescence and transmission images before bleaching and 600 sec after 
bleaching are shown. Total size of images: 2020 m. c, Relative FRAP at 300 sec of axonal segments close 
to or distant from (50 m distance) microglia prestimulated by the cytokines IFN-(100 U/ml) and IL-1(10 
ng/ml) for 72 hr. Data are presented as mean +/- SD. For each experimental condition, n=3. * = p<0.01. d, 
Relative FRAP at 300 sec of axonal segments close to or distant from (50 m distance) a cytokine-stimulated 
microglial cell. The microglia or the neurons were pretreated with the NO synthase inhibitor 
aminoguanidine (2mM). Data are presented as mean +/- SD. For each experimental condition, n=3. 
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Fig 4. Impaired axonal movement of synaptophysin-EGFP after NO donor application. a, Relative FRAP at 
300 sec in axons of neurons transfected with synaptophysin-EGFP and treated with NO donor (300 M 
DEA/NONOate). NO donor treatment reduced the axonal transport of synaptophysin-EGFP. 
Synaptophysin-EGFP transport was not modulated by cGMP (0.2 mM 8-bromo-cGMP) or aminoguanidine 
(2.5mM) treatment. Data are presented as mean +/- SD. For each experimental condition, n = 5. *p<0.05; 
**p<0.005. b, Half-time value (t1/2) of FRAP in axons of neurons transfected with synaptophysin-EGFP. 
The increase in t1/2 after 30 min of NO donor treatment indicates a decrease in the velocity of 
synaptophysin-EGFP movement. Data are presented as mean +/- SD. For each experimental condition, 
n=5. *p< 0.05. c, Mobile fraction in axons of neurons transfected with synaptophysin-EGFP. NO donor 
treatment significantly reduced the percentage of synaptophysin-EGFP moving along the axons. Data are 
presented as mean +/- SD. For each experimental condition, n = 5. ***p<0.001. 
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Fig 5. Impaired axonal movement of synaptophysin-EGFP after NO donor application depends on JNK 
phosphorylation. a, Relative FRAP at 300 sec in axons of neurons transfected with synaptophysin-EGFP 
and treated with NO donor (300 M DEA/NONOate). NO donor treatment reduced the axonal transport of 
synaptophysin-EGFP. Additional pretreatment with the JNK inhibitor (100 nM JNK inhibitor II) reverted 
the inhibitory effect of the NO donor on axonal motility. Data are presented as mean SD. For each 
experimental condition, n=5. *p0.05; **p0.005. b, Half-time value (t1/2) of FRAP in axons of neurons 
transfected with synaptophysin-EGFP. The increase in t1/2 after 30 min of NO donor treatment indicates a 
decrease in the velocity of synaptophysin-EGFP movement. Data are presented as mean SD. For each 
experimental condition, n=5. *p0.01. c, Mobile fraction of FRAP in axons of neurons transfected with 
synaptophysin-EGFP. NO donor treatment significantly reduced the percentage of synaptophysin-EGFP 
moving along the axons. Additional pretreatment with the JNK inhibitor (100nM JNK inhibitorII) reverted 
the inhibitory effect of the NO donor on the mobile fraction. Data are presented as mean +/- SD. For each 
experimental condition, n=5. *p<0.01; **p<0.005. 
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Fig 6. Immunohistochemistry of phosphorylated JNK in cultured hippocampal neurons. a, Neurons were 
identified by antibodies directed against the axonal marker protein tau (green). Only rare punctate staining 
of phosphorylated JNK (red) was detected in untreated neurons. Scale bar, 10 m. b, Phosphorylated JNK 
(red) was observed in most tau (green)-positive axons after treatment of the cultures with 300 M 
DEA/NONOate for 5 min. Area selected for inset as indicated. Scale bar, 10 m. c, Percentage of axons 
identified by immunolabeling with antibodies directed against tau that show double-labeling for 
phosphorylated JNK. Neurons are either untreated or treated with 300 M DEA/NONOate for 5, 10, or 15 
min. Data are presented as mean +/- SEM. ** =p<0.005. 
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Fig 7. Impaired axonal movement of synaptotagmin-EGFP after NO donor application. a, Neuron 
transfected with synaptotagmin-EGFP (green) and immunolabeled with antibodies directed against 
VAMP2 (red). Colocalization between synaptotagmin-EGFP and VAMP2 indicates expression of 
synaptotagmin-EGFP in synaptic vesicle precursors. Area selected for inset as indicated. Scale bar, 10 m. b, 
Relative FRAP at 300 sec in axons of neurons transfected with synaptotagmin-EGFP and treated with NO 
donor (300 M DEA/NONOate). NO donor treatment reduced the axonal transport of synaptotagmin-EGFP. 
Additional pretreatment with the JNK inhibitor (100 nM JNK inhibitor II) reverted the inhibitory effect of 
the NO donor on axonal transport. Data are presented as mean +/- SD. For each experimental condition, 
n=4. *=p<0.05; **=p<0.005. c, Half-time value (t1/2) of FRAP in axons of neurons transfected with 
synaptotagmin-EGFP. Data are presented as mean +/- SD. For each experimental condition, n=4. d, Mobile 
fraction of FRAP in axons of neurons transfected with synaptotagmin-EGFP. NO donor treatment 
significantly reduced the percentage of synaptotagmin-EGFP moving along the axons. Additional 
pretreatment with the JNK inhibitor (100 nM JNK inhibitor II) reverted the inhibitory effect of the NO 
donor on the mobile fraction. Data are presented as mean +/- SD. For each experimental condition, n=4. 
*=p<0.05; **=p<0.005. 
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Fig 8. Expression of TNF receptor I and II in axons of cultured neurons.  
A.Primary hippocampal neurons were immunolabeled with specific antibodies directed against TNF 
receptor I (green) and double labeled with specific antibodies directed against the axonal marker protein tau 
(red). B. Expression of TNF receptor I is detected on tau positive axons. Scale bar:  30  µm. Primary 
hippocampal neurons were immunolabeled with specific antibodies directed against TNF receptor II 
(green) and double labeled with specific antibodies directed against the axonal marker protein tau (red). 
Expression of TNF receptor II is detected on tau positive axons. Scale bar:  40 µm. 
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Fig 9. Immunodetection of phosphorylated JNK in axons after TNF-α treatment and complex formation 
between JNK, KIF5B and β-tubulin-III.  
a. Cultured hippocampal neurons were immunolabeled with specific antibodies directed against 
phosphorylated JNK (P-JNK; red) and co-labeled with antibodies directed against tau (Tau; green). In 
untreated neurons phosphorylated JNK was detected in cell bodies, but not in axons. Scale bar: 15 µm. 
b. Following treatment of neurons with TNF-α for 20 minutes strong labeling for phosphorylated JNK was 
observed in cell bodies and axons. Insets as indicated Scale bars: 20 µm. 
c. Number of axonal processes and cell bodies identified by co-labeling with antibodies directed against tau 
showing expression of phosphorylated JNK. Neurons were either untreated or treated with TNF-α for 20 
minutes. Data are presented as mean +/-  SEM.  ***= p<0.001 (two-tailed Mann-Whitney U test). 
d. Protein lysates of cultured hippocampal neurons were immunoprecipitated with specific antibodies 
directed against β-tubulin-III (Anti tub.) or KIF5B (Anti KIF5B). Immunoprecipitated proteins were 
analyzed by Western blotting with specific antibodies directed against β-tubulin-III (Anti tub.) or JNK 
(Anti JNK). JNK was detected in protein precipitates immunoselected for β-tubulin-III (Anti tub III) or 
KIF5B (Anti KIF5B). 
e. Protein lysates of cultured hippocampal neurons either untreated or treated with TNF-α for 20 minutes 
were immunoprecipitated with specific antibodies directed against β-tubulin-III (Anti tub.). 
Immunoprecipitated proteins were analyzed by Western blotting with specific antibodies directed against 
KIF5B (Anti KIF5B) or JNK (Anti JNK). No effect of TNF-α on the complex was observed. 
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Fig 10. Colocalization of KIF5B and β-tubulin-III in primary hippocampal neurons by confocal 
microscopy.  
Neurons were co-immunolabeled with antibodies directed against KIF5B marked with FITC and antibodies 
directed against β-tubulin-III marked with Cy3. Confocal images for KIF5B-FITC (green) and β-tubulin-
III-Cy3 (red) are shown for untreated cells (a), cells treated for 20 minutes with TNF-α (b) or cells treated 
with TNF-α for 20 minutes and the JNK inhibitor SP600125 (c). KIF5B co-localized with β-tubulin-III as 
determined by confocal microcopy. Scale bars: 20 µm. 
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Fig 11. Effects of TNF-α on the molecular interaction between KIF5B and tubulin-III as determined by 
lifetime based FRET analysis. Neurons were co-immunolabeled with antibodies directed against KIF5B 
marked with FITC and antibodies directed against β-tubulin-III marked with Cy3. Two-photon laser 
scanning single-photon counting lifetime images of KIF5B-FITC were obtained with a Becker-Hickl 
system. Lifetime images were acquired through a band-pass filter centered at 520 ± 15 nm to selectively 
acquire the FITC spectral band. Acquired lifetime values between 1.0 and 1.9 nanoseconds were coded in 
red and values between 1.9 and 4.0 nanoseconds were coded in green.  
a. In untreated neurons direct association between β-tubulin-III and KIF5B was observed as demonstrated 
by lifetime values coded in red. Scale bar: 20 µm. 
b. After treatment with TNF-α for 20 minutes the conformation of the KIF5B-β-tubulin-III complex 
changed in axons as demonstrated by lifetime values coded in green. Specifically, TNF-α induced a 
breakage of the normal KIF5B-β-tubulin-III complex in axons, but not in cell bodies. Insets as indicated. 
Scale bars: 20 µm. 
c. After JNK inhibition of TNF-α treated neurons the lifetime values partially reverted to levels comparable 
to untreated neurons indicating that JNK is involved in the TNF-α mediated changes on KIF5B-β-tubulin-
III complex in axons. Scale bar: 20 µm. 
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Fig 12. Effects of TNF-α on the molecular interaction between KIF5B and tubulin-III as determined by 
lifetime based FRET analysis. Neurons were co-immunolabeled with antibodies directed against KIF5B 
marked with FITC and antibodies directed against β-tubulin-III marked with Cy3. 
a. Lifetime histograms demonstrating a change in the KIF5B-β-tubulin-III complex after TNF-α treatment 
dependent on JNK phosphorylation. Untreated neurons (Untreated) co-labeled for KIF5b-FITC and β-
tubulin-III-Cy3 showed a shift of the lifetime distribution of FITC with a peak value of approximately 1.5 
nanoseconds compared to neurons (Control neurofilament) co-labeled with KIF5B-FITC and an irrelevant 
acceptor (neurofilament-Cy3) with a peak value of approximately 2.2 nanoseconds. After treatment with 
TNF-α for 20 minutes, neurons (TNF treated) co-labeled for KIF5B-FITC and β-tubulin-III-Cy3 showed a 
lifetime distribution with a peak value of 2.2 +/- 0.13 nanoseconds. TNF + JNK inhib.: Neurons co-labeled 
for KIF5b-FITC and β-tubulin-III-Cy3 and treated with TNF-α and JNK inhibitor. Control KIF5B: 
Untreated neurons labeled with KIF5B and without acceptor. 
b. Analysis of lifetime peak values in axons. Untreated neurons (Untreated) co-labeled for KIF5b-FITC and 
β-tubulin-III-Cy3 showed a shift of the lifetime distribution with a mean peak value of 2.3 +/- 0.5 
nanoseconds (mean +/- SD) compared to TNF-α treated neurons (TNF treated) with a mean peak value of 
1.5 +/- 0.18 nanoseconds or untreated neurons (Control neurofilament) co-labeled with KIF5B-FITC and 
neurofilament-Cy3 with a mean peak value of 2.25+/- 0.14 nanoseconds. Control KIF5B: Lifetime values 
of KIF5B after labelling of KIF5B-FITC alone. Data are presented as mean +/- SD. *** p<0.001; ** 
p<0.01 (t test). 
 c. Analysis of the percentage of axons showing short lifetime as a sign of molecular interaction between 
KIF5B-FITC and β-tubulin-III-Cy3. TNF-α treatment (TNF) induced breakage of the KIF5B-β-tubulin-III 
complex in almost all axons, while co-treatment of neurons with JNK inhibitor and TNF-α (TNF plus JNK 
inhib.) prevented the conformational change in the   KIF5B-β-tubulin-III complex. Control neurofilament: 
Axons showing long lifetime after co-labelling of KIF5B-FITC and neurofilament-Cy3. Control KIF5B: 
Axons showing long lifetime after labelling of KIF5B-FITC without acceptor alone. Data are presented as 
mean +/- SD. *** p<0.001 (Mann Whitney U  test).  
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Fig 13. Inhibition of mitochondria movements by TNF-α via JNK. Cultured hippocampal neurons were 
transfected with a mitochondrial targeting sequence tagged to YFP (Mito-YFP) and scanned by time lapse 
confocal microscopy.  
a. Images of mitochondrial movements were collected each 20 seconds and analyzed in the horizontal and 
vertical kymograph. The first image collected and the corresponding kymographs over 20 minutes are 
shown from a representative untreated axon. Scale bar: 10 µm. 
b. The percentage of mitochondria moving along axons (mobile fraction) anterogradely and retrogradely 
was quantified in neurons transfected with a mitochondrial targeting sequence tagged to YFP. Treatment of 
neurons with TNF-α for 20 minutes reduced the mobile fraction. At 360 minutes after TNF-α treatment the 
movement of mitochondria reverted to normal levels. Effect of TNF-α on mitochondrial movement was 
neutralized by inhibition of JNK with SP600125 (JNK inhibitor). Furthermore, the effect of TNF-α on 
axonal mitochondria movement was inhibited by blocking TNF-α with a TNFRI-IgG-fusion protein (TNF 
inhibition). Data are presented as mean +/- SD. *** p<0.001 ** p<0.01 (Mann Whitney U  test).   
c. The velocity of mitochondria moving along axons anterogradely and retrogradely was quantified in 
neurons transfected with a mitochondrial targeting sequence tagged to YFP. No change in velocity was 
observed after treatment with TNF-α or combined treatment with TNF-α and JNK inhibitor. Data are 
presented as mean +/- SD. 
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Fig 14. Inhibition of synaptophysin movements by TNF-α via JNK. Cultured hippocampal neurons were 
transfected with synaptophysin-GFP and scanned by FRAP confocal microscopy.  
a. Images of synaptophysin-GFP movements were collected every 20 seconds after photobleaching of a 20 
µm axonal segment. Selected images before bleaching and 2, 4, 6, 8 and 10 minutes after bleaching are 
shown. Scale bar: 7 µm. 
b. Relative FRAP at 300 seconds in axons of neurons transfected with synaptophysin-GFP and treated with 
TNF-α or TNF-α plus JNK inhibitor. TNF-α treatment reduced the axonal transport of synaptophysin-GFP. 
The effect of TNF-α on synaptophysin-GFP transport was neutralized by JNK inhibition. Data are 
presented as mean +/- SD. For each experimental condition n > 10.  ***p< 0.001. (t test) 
c. Mobile fraction of FRAP in axons of neurons transfected with synaptophysin-GFP. TNF-α treatment 
significantly reduced the percentage of synaptophysin-GFP moving along the axons. Data are presented as 
mean +/- SD. For each experimental condition n > 10. ***p< 0.001. (t test) 
d. Half-time value (t½) of FRAP in axons of neurons transfected with synaptophysin-GFP. No significant 
change in t½ was observed after TNF-α treatment indicating that TNF-α does not modulate the velocity of 
the remaining synaptophysin-GFP moving along axons. Data are presented as mean +/- SD. For each 
experimental condition n > 10.  
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Fig 15. Immunohistochemistry for neurofilament and tau after FRAP analysis. Cultured hippocampal 
neurons were transfected with synaptophysin-EGFP (Syn-EGFP; green) and FRAP was performed at the 
axon (bleached area as indicated in the images). Neurons were fixed in immunolabeled with specific 
antibodies direct against neurofilament (blue) and tau (red). No difference in the immunolabelling of the 
cytoskeleton is detected between the bleached and unbleached areas of the axon, indicating that the 
photobleaching of synaptophysin-EGFP does not harm the axonal cytoskeleton. Scale bar: 20 µm. 
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Table: No change in axonal transport of synaptophysin-EGFP after re-analysis of 
the same neuron. Cultured hippocampal neurons were transfected with synaptophysin-
EGFP. Axons of transfected neurons were analyzed by fluorescence recovery after 
photobleaching (FRAP). After 24 hours the axons of the same neurons were identified 
and re-analyzed by FRAP. No significant difference (Man Whitney U-test, p > 0.8; n=5) 
was found for any measured parameter between the first and second FRAP analysis 24 
hours later indicating that the photobleaching procedure does not cause damage to 
neurons. 
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Table: Levels of NO used in our experiments (300µM) do not cause cell death. 
Hippocampal neurons were treated with varying concentrations of NO donor, and 
assessed for survival 24hours after treatment.  
 
APPENDIX 1 : Abbreviations 
 
APP Amyloid Precursor Protein 
C57BL/6 Mice strain 
CD Cluster of Differentiation 
cGMP Cyclic guanosine monophosphate  
DEA/NONAde Nitric Oxide Donor 
EGFP Enhanced Green Fluorescence Protein 
EYFP Enhanced Yellow Fluorescence Protein 
FCS Fetal Calf Serum 
FITC Fluoro-Isothiocyanate 
FRAP Fluorescence Recovery After Photobleaching 
FRET Föster Resonance Energy Transfert 
GAPDH Glyseraldehyde-3-phosphate dehydrogenase  
Ig Immuno Globuline 
IL-beta Interleukin beta 
INF-gamma Interferon gamma 
iNOS Inducible Nitric Oxide Synthethase 
JIP c-Jun N terminal Kinase Interaction Protein 
JNK c-Jun N terminal Kinase 
KIF1A Kinesin Motor Protein Family 1a 
KIF5B Kinesin Motor Protein Family 5b 
MAP2 Microtubule Associated Protein 2 
NFKappaB Nuclear Factor Kappa-B,  
NO Nitric Oxide 
NOS Nitric Oxide Synthethase 
p38 Synaptophysin 
p65 Synaptotagmin 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PMT PhotoMultiplier Tubes 
SP600125 Jun N-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazol-6(2H)-one 
TD-FLIM Time-domain Fluorescence lifetime imaging microscope  
TNF-alpha Tumor Necrosis Factor Alpha 
VAMP2 Vesicle-Associated Membrane Protein 2 
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J Neurosci. 2005 Jan 12;25(2):352-62. 
Breakdown of axonal synaptic vesicle precursor transport by microglial nitric oxide. 
 
Stagi M, Dittrich PS, Frank N, Iliev AI, Schwille P, Neumann H. 
 
The mechanism of axonal injury in inflammatory brain diseases is still unclear. Increased microglial 
production of nitric oxide (NO) is a common early sign in neuroinflammatory diseases. We found by 
fluorescence correlation spectroscopy that synaptophysin tagged with enhanced green fluorescence protein 
(synaptophysin-EGFP) moves anterogradely in axons of cultured neurons. Activated microglia focally 
inhibited the axonal movement of synaptophysin-EGFP in a NO synthase-dependent manner. Direct 
application of a NO donor to neurons resulted in inhibition of axonal transport of synaptophysin-EGFP and 
synaptotagmin I tagged with EGFP, mediated via phosphorylation of c-jun NH2-terminal kinase (JNK). 
Thus, overt production of reactive NO by activated microglia blocks the axonal transport of synaptic 
vesicle precursors via phosphorylation of JNK and could cause axonal and synaptic dysfunction. 
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LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. 
 
Liu Y, Stagi M, Walter S, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke 
B, Neumann H, Fassbender K. 
 
The amyloid beta peptide 42 (Abeta(42)) plays a key role in neurotoxicity in Alzheimer's disease. 
Mononuclear phagocytes, i.e. microglia, have the potential to clear Abeta by phagocytosis. Recently, the 
lipopolysaccharide (LPS) receptor CD14 was shown to mediate phagocytosis of bacterial components and 
furthermore to contribute to neuroinflammation in Alzheimer's disease. Here, we investigated whether this 
key innate immunity receptor can interact with Abeta(42) and mediate phagocytosis of this peptide. Using 
flow cytometry, confocal microscopy and two-photon fluorescence lifetime imaging (FLIM) combined 
with fluorescence resonance energy transfer (FRET), we demonstrated a direct molecular interaction in the 
range of a few nanometers between Abeta(42) and CD14 in human CD14-transfected Chinese hamster 
ovary cells. Investigations using cells that were genetically deficient for this receptor showed that in <30 
minutes exogenous Abeta(42) added to cultured primary microglial cells was phagocytosed into the 
cytoplasmic compartment in a CD14-dependent manner. This phagocytosis occurred at Abeta(42) 
concentration ranges that were considerably lower than the threshold to activate a cellular inflammatory 
reaction. In contrast, there was no association of CD14 to microglial internalization of microbeads. In 
complementary clinical experiments, we detected a pronounced CD14 immunoreactivity on parenchymal 
microglia spatially correlated to characteristic Alzheimer's disease lesion sites in brain sections of 
Alzheimer's disease patients but not in brain sections of control subjects. By showing a close interaction 
between CD14 and Abeta(42), demonstrating a direct role of CD14 in Abeta(42) phagocytosis, and 
detecting CD14-specific staining in brains of Alzheimer's disease patients, our results indicate a role of the 
LPS receptor in the pathophysiology of Alzheimer's disease, which could be of therapeutic relevance. 
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Unloading kinesin transported axonal cargoes from the tubulin track via the 
inflammatory c-Jun N-terminal kinase pathway 
 
Stagi M, Gorlovoy P, Takahashi K and Neumann H 
 
Axonal transport of mitochondria and synaptic vesicle precursors via kinesin motor protein is essential to 
keep integrity of axons and synapses. Disturbance of axonal transport is an early sign of neuroinflammatory 
and neurodegenerative diseases. Treatment of cultured neurons by the inflammatory cytokine tumor 
necrosis factor-α (TNF) stimulated phosphorylation of c-Jun N-terminal kinase (JNK) in axons. TNF 
treatment induced dissociation of the heavy chain kinesin family-5B (KIF5B) protein from tubulin in 
axons, but not cell bodies as determined by lifetime-based Förster resonance energy transfer (FRET) 
analysis. Dissociation of KIF5B from tubulin after TNF treatment was dependent on phosphorylation of 
JNK. Furthermore, TNF inhibited axonal transport of mitochondria and synaptophysin by reducing the 
mobile fraction via JNK. Thus, TNF produced by activated glial cells in inflammatory or degenerative 
neurological diseases acts on axons by breaking apart the kinesin-tubulin complex and inhibits axonal 
mitochondria and synaptophysin transport via phosphorylation of JNK. 
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Repair Therapy of experimental autoimmune encephalomyelitis by TREM2-
transduced myeloid cells  
 
Takahashi K, Prinz M, Stagi M, and Harald Neumann 
 
In experimental models of multiple sclerosis, inflammation can successfully be prevented, while promoting 
repair is still a major challenge for therapy. Bone marrow or blood-derived hematopoietic precursor cells 
are suitable and easy accessible sources for cell-based repair therapies. Efficient removal of apoptotic cells 
and cellular debris without inflammation during degenerative central nervous system (CNS) diseases is 
essential for repair of the injured tissue and disease recovery 1,2. Recently we discovered that the 
microglial triggering receptor expressed on myeloid cells-2 (TREM2) stimulates phagocytosis and down-
regulates inflammatory signals in microglia 3. Here we show that intravenous cell therapy by TREM2-
transduced myeloid cells at the disease peak of experimental autoimmune encephalomyelitis (EAE) leads to 
a significant amelioration of clinical symptoms, reduction in axonal damage and prevention of 
demyelination. After intravenous application, the TREM2-transduced myeloid cells migrated into the 
inflammatory spinal cord lesions within 2 hours, showed increased phagocytosis and created an anti-
inflammatory cytokine milieu within the spinal cord. The TREM2 expressing myeloid cells shut off 
negative cycles of inflammation by removing cellular debris and creating a milieu supportive for repair of 
injured tissue. Thus, we identified TREM2 as a novel target for the ex vivo cell therapy of inflammatory 
autoimmune brain diseases. 
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“Sulla difficolta´ della ricerca. 
 
Io ho disfatto piu di dieci corpi umani , sminuzzando tutta la carne che si trovava 
intorno alle vene, per metterle a nudo e poterle disegnare; e per ottenere questi disegni  
non basta l´amore per la ricerca, perche´ tu potresti essere impedito dallo stomaco, dalla 
ripugnanza o potresti essere impedito dalla paura con l´abitare di notte in compagnia di 
morti squartati e scorticati, spaventosi a vedersi, e se questo non ti impedisce forse ti 
manchera´ la sapienza del disegno””  
(Leonardo Da Vinci, 1452) 
 
 
“On the difficulties of research. 
 
I have destroyed more than ten human bodies, hashed all that meat around the veins, to 
strip them naked so as to draw them. To obtain these drawings, it is not enough to love 
research, as you maybe hindered by weakness of stomach, by repugnance, or you may 
fear to work nights in the company of the flayed and quartered dead, terrible to see. 
And if all this does not impede you, you may yet lack the talent to draw.“  
(Leonardo Da Vinci, 1452) 
 
